Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity

Here, we present the molecular diagnosis of a patient with a general clinical suspicion of Mucopolysaccharidosis, highlighting the different tools used to perform its molecular characterization. In order to decrease the turnaround time for the final report and contribute to reduce the “dia...

Full description

Bibliographic Details
Main Authors: Maria Francisca Coutinho, Marisa Encarnação, Liliana Matos, Lisbeth Silva, Diogo Ribeiro, Juliana Inês Santos, Maria João Prata, Laura Vilarinho, Sandra Alves
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/10/2/58
id doaj-31331fcb53034953abc929eac3eadb2e
record_format Article
spelling doaj-31331fcb53034953abc929eac3eadb2e2020-11-25T02:05:44ZengMDPI AGDiagnostics2075-44182020-01-011025810.3390/diagnostics10020058diagnostics10020058Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its PathogenicityMaria Francisca Coutinho0Marisa Encarnação1Liliana Matos2Lisbeth Silva3Diogo Ribeiro4Juliana Inês Santos5Maria João Prata6Laura Vilarinho7Sandra Alves8Research and Development Unit, Department of Human Genetics, INSA, 4000-055 Porto, PortugalResearch and Development Unit, Department of Human Genetics, INSA, 4000-055 Porto, PortugalResearch and Development Unit, Department of Human Genetics, INSA, 4000-055 Porto, PortugalResearch and Development Unit, Department of Human Genetics, INSA, 4000-055 Porto, PortugalResearch and Development Unit, Department of Human Genetics, INSA, 4000-055 Porto, PortugalResearch and Development Unit, Department of Human Genetics, INSA, 4000-055 Porto, PortugalBiology Department, Faculty of Sciences, University of Porto, 4150-179 Porto, PortugalResearch and Development Unit, Department of Human Genetics, INSA, 4000-055 Porto, PortugalResearch and Development Unit, Department of Human Genetics, INSA, 4000-055 Porto, PortugalHere, we present the molecular diagnosis of a patient with a general clinical suspicion of Mucopolysaccharidosis, highlighting the different tools used to perform its molecular characterization. In order to decrease the turnaround time for the final report and contribute to reduce the &#8220;diagnostic odyssey&#8221;, which frequently afflicts affected families, the proband&#8217;s sample was simultaneously screened for mutations in a number of lysosomal function-related genes with targeted next-generation sequencing (NGS) protocol. After variant calling, the most probable cause for disease was a novel <i>ARSB</i> intronic variant, c.1213+5G&gt;T [IVS6+5G&gt;T], detected in homozygosity. In general, homozygous or compound heterozygous mutations in the <i>ARSB</i> gene, underlie MPS type VI or Maroteaux-Lamy syndrome. Still, even though the novel c.1213+5G&gt;T variant was easy to detect by both NGS and Sanger sequencing, only through indirect studies and functional analyses could we present proof of principle on its pathogenicity. Globally, this case reminds us that whenever a novel variant is detected, its pathogenicity must be carefully assessed before a definitive diagnosis is established, while highlighting alternative approaches that may be used to assess its effect in the absence RNA/cDNA sample(s) from the proband. This is particularly relevant for intronic variants such as the one here reported. Special attention will be given to the use of reporter minigene systems, which may be constructed/designed to dissect the effect of this sort of alterations, providing an insight into their consequences over the normal pre-mRNA splicing process of the affected gene.https://www.mdpi.com/2075-4418/10/2/58mucopolysaccharidosis type vi (mps vi)lysosomal storage disorders (lsds)next-generation sequencing (ngs)splicing mutationfunctional studies
collection DOAJ
language English
format Article
sources DOAJ
author Maria Francisca Coutinho
Marisa Encarnação
Liliana Matos
Lisbeth Silva
Diogo Ribeiro
Juliana Inês Santos
Maria João Prata
Laura Vilarinho
Sandra Alves
spellingShingle Maria Francisca Coutinho
Marisa Encarnação
Liliana Matos
Lisbeth Silva
Diogo Ribeiro
Juliana Inês Santos
Maria João Prata
Laura Vilarinho
Sandra Alves
Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity
Diagnostics
mucopolysaccharidosis type vi (mps vi)
lysosomal storage disorders (lsds)
next-generation sequencing (ngs)
splicing mutation
functional studies
author_facet Maria Francisca Coutinho
Marisa Encarnação
Liliana Matos
Lisbeth Silva
Diogo Ribeiro
Juliana Inês Santos
Maria João Prata
Laura Vilarinho
Sandra Alves
author_sort Maria Francisca Coutinho
title Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity
title_short Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity
title_full Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity
title_fullStr Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity
title_full_unstemmed Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity
title_sort molecular characterization of a novel splicing mutation underlying mucopolysaccharidosis (mps) type vi—indirect proof of principle on its pathogenicity
publisher MDPI AG
series Diagnostics
issn 2075-4418
publishDate 2020-01-01
description Here, we present the molecular diagnosis of a patient with a general clinical suspicion of Mucopolysaccharidosis, highlighting the different tools used to perform its molecular characterization. In order to decrease the turnaround time for the final report and contribute to reduce the &#8220;diagnostic odyssey&#8221;, which frequently afflicts affected families, the proband&#8217;s sample was simultaneously screened for mutations in a number of lysosomal function-related genes with targeted next-generation sequencing (NGS) protocol. After variant calling, the most probable cause for disease was a novel <i>ARSB</i> intronic variant, c.1213+5G&gt;T [IVS6+5G&gt;T], detected in homozygosity. In general, homozygous or compound heterozygous mutations in the <i>ARSB</i> gene, underlie MPS type VI or Maroteaux-Lamy syndrome. Still, even though the novel c.1213+5G&gt;T variant was easy to detect by both NGS and Sanger sequencing, only through indirect studies and functional analyses could we present proof of principle on its pathogenicity. Globally, this case reminds us that whenever a novel variant is detected, its pathogenicity must be carefully assessed before a definitive diagnosis is established, while highlighting alternative approaches that may be used to assess its effect in the absence RNA/cDNA sample(s) from the proband. This is particularly relevant for intronic variants such as the one here reported. Special attention will be given to the use of reporter minigene systems, which may be constructed/designed to dissect the effect of this sort of alterations, providing an insight into their consequences over the normal pre-mRNA splicing process of the affected gene.
topic mucopolysaccharidosis type vi (mps vi)
lysosomal storage disorders (lsds)
next-generation sequencing (ngs)
splicing mutation
functional studies
url https://www.mdpi.com/2075-4418/10/2/58
work_keys_str_mv AT mariafranciscacoutinho molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
AT marisaencarnacao molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
AT lilianamatos molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
AT lisbethsilva molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
AT diogoribeiro molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
AT julianainessantos molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
AT mariajoaoprata molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
AT lauravilarinho molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
AT sandraalves molecularcharacterizationofanovelsplicingmutationunderlyingmucopolysaccharidosismpstypeviindirectproofofprincipleonitspathogenicity
_version_ 1724937324884656128